JO
DOVA

John Overdeck’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

John Overdeck’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-17,900
Closed -$136K – 3642
2018
Q4 		$136K Buy
+17,900
New +$288K ﹤0.01% 2779

Other funds holding DOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

John Overdeck's DOVA Position: Q1 2019 in Review

John Overdeck sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q1 2019, closing a stake of 17,900 shares — an estimated $136K sold.

John Overdeck first reported a position in DOVA in Q4 2018 and held it in 1 quarter. The position peaked at $136K in Q4 2018. 59 funds tracked by Wall St. Rank hold DOVA as of Q1 2019.

  • John Overdeck reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • John Overdeck sold 17,900 Dova Pharmaceuticals, Inc. Common Stock shares in Q1 2019, an estimated $136K.
  • John Overdeck first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • John Overdeck's Dova Pharmaceuticals, Inc. Common Stock position peaked at $136K in Q4 2018.
  • 59 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q1 2019.

Based on Two Sigma Investments's 13F filing for Q1 2019, filed 15 May 2019.